Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
These treatments pave the way for women to achieve better health, manage their metabolism, and maintain steady weight loss
These drugs aid glycemic control through multiple mechanisms like enhancing insulin secretion, suppressing glucagon levels, and reducing appetite to induce weight loss
Unlike current GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), Retatrutide is a triple hormone receptor agonistactivating GLP-1, GIP, and glucagon receptors simultaneously
If you are participating in a clinical trial and experience any severe or persistent symptoms, contact your trial team immediately
Retatrutide is an investigational triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors currently in Phase 3 trials with no global regulatory approval
US$ 22.96
US$ 23.81
US$ 25.52
US$ 24.95
US$ 21.20
US$ 29.01
US$ 24.65
US$ 29.49
